Notably, despite low ISGylation activity in mice, overexpression of ISG15 significantly enhances the therapeutic effect of anti-PD-L1 in a mouse model of LC, suggesting that even limited ISGylation can effectively mediate PD-L1 degradation when ISG15 is locally expressed. Here, ISG15 is linked to laryngotracheoesophageal cleft.